LISATA THERAPEUTICS, INC. — Form 8-K/A
Filed November 12, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 75/100
What the filing says
On September 17, 2026, Lisata Therapeutics acquired the combined Marea/M2 entities via merger. Lisata issued 1,793,129 shares of common stock and 211,365.213 shares of Series C Preferred Stock (convertible into 211.365M common shares) to former Marea/M2 holders. Concurrent PIPE raised ~$225M. Post-transaction ownership: Lisata pre-holders ~2.39%, former Marea/M2 holders ~59.54%, PIPE investors ~38.07% (fully-diluted basis).
Why this rating
Major M&A event: $23.6M company acquired by public acquirer with $225M capital raise. Provides liquidity, funding runway, and access to capital markets. Positive for Marea/M2 but dilutes original shareholders significantly.
Tradability signal
NO TRADE
No trade: only ~$47k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.14 ▼ 5.00% | at our read · unknown $1.20 | +10 min · unknown $1.22 ▲ 1.67% | +30 min · unknown $1.18 ▼ 1.67% | +1 hr · unknown $1.27 ▲ 5.83% | +4 hrs · unknown $1.23 ▲ 2.50% |
The stock had already moved +5.26% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.